The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Comparing the efficacy of VRd versus VCd as induction therapy in multiple myeloma
In this video, Fredrik Schjesvold, MD, PhD, Oslo Myeloma Center, Oslo, Norway, discusses a population-based study evaluating the efficacy of different induction regimens for patients with multiple myeloma. The study analyzed 2,000 patients and found that the VRd regimen (bortezomib, lenalidomide and dexamethasone) outperformed VCd (bortezomib, cyclophosphamide and dexamethasone) in terms of response rates before and after transplant, progression-free survival (PFS), and overall survival (OS). This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
